Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 8/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | UQCRB | P14927 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.51 |
| ▸ | CCR9 | P51686 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28597367 | 0.88 | KEAP1 (0.60) | HSD17B2ALDH1A1LMNACA1CA2 | |
| SCHEMBL15248886 | 0.85 | HSD17B2 (0.74) | HSD17B2ALDH1A1KDM4ELMNAUQCRB | |
| SCHEMBL12096937 | 0.85 | HSD17B2 (0.52) | HSD17B2ALDH1A1KDM4ELMNA | |
| SCHEMBL2968297 | 0.84 | HSD17B2 (0.67) | HSD17B2CCR9 | |
| SCHEMBL1631204 | 0.83 | HSD17B2 (0.71) | HSD17B2ALDH1A1KDM4ELMNAUQCRB | |
| SCHEMBL17849556 | 0.83 | HSD17B2 (0.71) | HSD17B2ALDH1A1KDM4ELMNAUQCRB | |
| SCHEMBL13852837 | 0.81 | HSD17B2 (0.68) | HSD17B2ALDH1A1KDM4ELMNAUQCRB | |
| SCHEMBL17849570 | 0.80 | HSD17B2 (0.66) | HSD17B2ALDH1A1KDM4ELMNAUQCRB | |
| SCHEMBL12096791 | 0.77 | HSD17B2 (0.46) | HSD17B2LMNAUQCRBCA1CA2 | |
| SCHEMBL4651332 | 0.77 | HSD17B2 (0.66) | HSD17B2ALDH1A1KDM4ELMNAUQCRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331302-A1 | N-(2-(HETARYL)ARYL) ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7776877-B2 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CHEMOCENTRYX, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090005410-A1 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CHEMOCENTRYX, INC. (US) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331302-A1 | N-(2-(HETARYL)ARYL) ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES | CCR9, CCR2, CCR10 | HSD17B2 1177/4885ALDH1A1 2087/4885KDM4E 4231/4885 |
| US-20090005410-A1 | N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation | CCR9, CCR1, CCR2 | HSD17B2 3385/4885ALDH1A1 2024/4885KDM4E 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.